These toxicity studies in mice were conducted by trypanosomiasis researchers at Makerere University in Uganda. The Makerere researchers reported that Upstream’s trypanosomiasis candidates were well tolerated by mice with no signs of serious toxicity at therapeutic dosages suggested by the in vitro experiments assessing the anti-malarial activity of these drug candidates.
Joel Bellenson, CEO of Upstream, said: “We look forward to advancing the preclinical program for these compounds that have the potential to significantly contribute to the health and economic vitality of this important region.”